Holen Sie sich die Stockscreener-App
1.53
1.32%
0.02
Handel nachbörslich:
1.53
Schlusskurs vom Vortag:
$1.51
Offen:
$1.51
24-Stunden-Volumen:
6.55M
Relative Volume:
2.00
Marktkapitalisierung:
$343.84M
Einnahmen:
$95,000
Nettoeinkommen (Verlust:
$-327.27M
KGV:
-0.7217
EPS:
-2.12
Netto-Cashflow:
$-239.25M
1W Leistung:
-2.55%
1M Leistung:
+10.87%
6M Leistung:
+2.00%
1J Leistung:
-20.73%
1-Tages-Spanne:
$1.49
$1.62
1-Wochen-Bereich:
$1.46
$1.83
52-Wochen-Spanne:
$0.8621
$3.78
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Firmenname
Allogene Therapeutics Inc
Sektor
Branche
Telefon
(650) 457-2700
Adresse
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Vergleichen Sie ALLO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.53 | 339.34M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-09 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-10-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-05-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | Fortgesetzt | Oppenheimer | Outperform |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-01-05 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | Eingeleitet | Citigroup | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-06 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-08-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | Hochstufung | Goldman | Neutral → Buy |
| 2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-02-28 | Bestätigt | B. Riley Securities | Buy |
| 2021-10-20 | Eingeleitet | Cowen | Outperform |
| 2021-10-08 | Herabstufung | Goldman | Buy → Neutral |
| 2021-10-08 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | Fortgesetzt | Jefferies | Buy |
| 2021-05-20 | Hochstufung | Truist | Hold → Buy |
| 2021-05-14 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-26 | Hochstufung | Stifel | Hold → Buy |
| 2020-12-10 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-11-24 | Eingeleitet | BofA Securities | Buy |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-06-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-19 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2020-05-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-05-14 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-14 | Herabstufung | SunTrust | Buy → Hold |
| 2020-04-13 | Eingeleitet | SunTrust | Buy |
| 2020-03-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-24 | Eingeleitet | Berenberg | Hold |
| 2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-11-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-06-05 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-31 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-23 | Eingeleitet | Stifel | Hold |
| 2019-03-29 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Allogene Therapeutics Inc Aktie (ALLO) Neueste Nachrichten
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Insider Selling: Allogene Therapeutics (NASDAQ:ALLO) EVP Sells 26,269 Shares of Stock - MarketBeat
Take Profit: What are the future prospects of Allogene Therapeutics IncBear Alert & Weekly Momentum Stock Picks - baoquankhu1.vn
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T - ADVFN
Insider Trends: What are the future prospects of Allogene Therapeutics IncTrade Risk Report & Fast Moving Stock Watchlists - baoquankhu1.vn
Decliners Report: Is AMZE part of any ETF2025 Winners & Losers & Safe Entry Zone Tips - baoquankhu1.vn
Earnings Miss: Is Allogene Therapeutics Inc stock a top momentum play - Bộ Nội Vụ
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Sell Signal: What are the risks of holding Allogene Therapeutics Inc2025 Technical Overview & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Earnings Risk: Will Allogene Therapeutics Inc stock hit new highs in YEARJobs Report & Weekly Market Pulse Alerts - baoquankhu1.vn
Allogene Therapeutics Sees Bright Prospects with Upgrades and Awards - StocksToTrade
Allogene Therapeutics Sees Optimistic Outlook as Market Interest Grows - timothysykes.com
Allogene Therapeutics Stock Surges After Promising Market Developments - timothysykes.com
Allogene Therapeutics’ Stock Surges as Analysts Optimistic on Future Outlook - StocksToTrade
Allogene Therapeutics Stock Rises Amid Key Developments - StocksToTrade
Allogene Therapeutics Stock Upgraded as ALPHA3 Trial Inspires Market Confidence - timothysykes.com
Allogene Therapeutics Surges on Positive Analyst Ratings and Arbitration Wins - timothysykes.com
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? - sharewise.com
Allogene Therapeutics (ALLO) Upgraded by Citizens to Market Outp - GuruFocus
Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results - MSN
Citizens Upgrades Allogene Therapeutics (ALLO) - Nasdaq
Allogene Therapeutics (ALLO) Upgraded to Outperform with Significant Upside - GuruFocus
Allogene upgraded at Citizens on discounted EPS, revenue multiple - Seeking Alpha
CG Oncology, Rich Sparkle Holdings, Liquidia And Other Big Stocks Moving Higher On Friday - Benzinga
Allogene Therapeutics (NASDAQ:ALLO) Upgraded at Citizens Jmp - MarketBeat
Allogene Therapeutics (NASDAQ:ALLO) Upgraded to Strong-Buy at UBS Group - MarketBeat
Citizens upgrades Allogene stock rating to Market Outperform on cancer therapy potential - Investing.com
Allogene In Focus: Can ALLO-316 Signal The Breakthrough CAR T Has Been Waiting For In Solid Tumors? - RTTNews
Why Allogene Therapeutics Inc. stock is favored by pension fundsWeekly Profit Report & Free AI Powered Buy and Sell Recommendations - Улправда
Is Allogene Therapeutics Inc. stock a buy before product launchesRate Hike & Smart Money Movement Tracker - Улправда
Published on: 2026-01-08 23:56:20 - ulpravda.ru
Will Allogene Therapeutics Inc. stock reach Wall Street targetsJuly 2025 Decliners & Fast Gain Stock Trading Tips - Улправда
Can Allogene Therapeutics Inc. stock outperform in 2025 bull market2025 Major Catalysts & Risk Managed Trade Strategies - Улправда
How Allogene Therapeutics Inc. stock reacts to bond yieldsEarnings Growth Report & Consistent Profit Trade Alerts - Улправда
Allogene outlines 2026 clinical milestones for off-the-shelf CAR T - Investing.com India
Allogene Therapeutics, Inc. Positions 2026 as Program-Defining Year for Scalable, Real-World Allogeneic CAR T - marketscreener.com
Allogene Therapeutics interim futility analysis of MRD clearance from phase 2 Alpha3 trial planned for early Q2 2026 - marketscreener.com
Allogene outlines 2026 clinical milestones for off-the-shelf CAR T By Investing.com - Investing.com South Africa
Is Allogene Therapeutics Inc. stock a buy in volatile marketsQuarterly Earnings Review & Access Risk Ratings for Every Stock - Улправда
UBS Initiates Coverage of Allogene Therapeutics (ALLO) with Buy Recommendation - Nasdaq
UBS Initiates Coverage on Allogene Therapeutics (ALLO) with 'Buy' Rating | ALLO Stock News - GuruFocus
UBS initiates coverage on Allogene stock with Buy rating, $8 price target By Investing.com - Investing.com South Africa
UBS initiates coverage on Allogene stock with Buy rating, $8 price target - Investing.com Canada
Allogene Therapeutics (NASDAQ:ALLO) Trading 4.4% HigherHere's Why - MarketBeat
Allogene stock hits 52-week low at $1.76 amid market challenges - MSN
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and Allogene Therapeutics (ALLO) - The Globe and Mail
Is Allogene Therapeutics Inc. stock attractive for growth ETFsQuarterly Growth Report & Real-Time Volume Spike Alerts - Улправда
Finanzdaten der Allogene Therapeutics Inc-Aktie (ALLO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):